Nimotuzumab Plus Paclitaxel and Cisplatin as a 1^st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study.

ABSTRACT: The effect of anti-epidermal growth factor receptor targeted treatment in esophageal squamous cell carcinoma (ESCC) is still unclear. We conducted a prospective phase II study of paclitaxel, cisplatin, and nimotuzumab (TPN) as a first-line treatment for unresectable or metastatic ESCC and the objective response rate was 51.8%. Here, we report the long-term follow-up results of the initial trial. Fifty-nine patients were enrolled from Mar 2011 to Apr 2013 and were treated with the TPN regimen. Palliative sequential radiotherapy was given if all tumor lesions were confined to 1-2 radiation fields. Fifty-six patients were eligible for evaluation. After a median follow-up of 32.2months, the median progression-free survival (PFS) and the overall survival (OS) time were 18.1±4.2 months (95% CI:

SUBMITTER: Zhang X 

PROVIDER: S-EPMC6485235 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature